Partnership expands Novartis's oncology pipeline.
2 reports, 2 independent
Updated Aug 28
Gone quiet
- Reports
- 2
- Developments
- 4
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Partnership expands Novartis's oncology pipeline.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Clinical trials for a CAR-T therapy, rap-cel, have been paused due to severe adverse events.Sub-event
Novartis received EC authorization for REDEMPLO, validating its pipeline and commercial strategy.1 source
- Novartis halted drug development while Northwell Health continues research on related projects.Sub-event
Novartis expands its oncology pipeline through a new partnership.1 source
Keep exploring
The entities involved
-
Novartis
Swiss-American multinational pharmaceutical corporation